Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

888 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Identification of lenvatinib prognostic index via recursive partitioning analysis in advanced hepatocellular carcinoma.
Rapposelli IG, Shimose S, Kumada T, Okamura S, Hiraoka A, Di Costanzo GG, Marra F, Tamburini E, Forgione A, Foschi FG, Silletta M, Lonardi S, Masi G, Scartozzi M, Nakano M, Shibata H, Kawata K, Pellino A, Vivaldi C, Lai E, Takata A, Tajiri K, Toyoda H, Tortora R, Campani C, Viola MG, Piscaglia F, Conti F, Fulgenzi CAM, Frassineti GL, Rizzato MD, Salani F, Astara G, Torimura T, Atsukawa M, Tada T, Burgio V, Rimini M, Cascinu S, Casadei-Gardini A. Rapposelli IG, et al. Among authors: okamura s. ESMO Open. 2021 Aug;6(4):100190. doi: 10.1016/j.esmoop.2021.100190. Epub 2021 Jun 16. ESMO Open. 2021. PMID: 34144271 Free PMC article.
Dose and Location of Irradiation Determine Survival for Patients with Hepatocellular Carcinoma with Macrovascular Invasion in External Beam Radiation Therapy.
Iwamoto H, Nomiyama M, Niizeki T, Shimose S, Shirono T, Nakano M, Satani M, Okamura S, Noda Y, Kamachi N, Sakai M, Suzuki H, Kuromatsu R, Ogo E, Abe T, Tanaka M, Koga H, Torimura T. Iwamoto H, et al. Among authors: okamura s. Oncology. 2019;96(4):192-199. doi: 10.1159/000495568. Epub 2019 Jan 16. Oncology. 2019. PMID: 30650415
Genomic correlates of response and resistance to the irreversible FGFR1-4 inhibitor futibatinib based on biopsy and circulating tumor DNA profiling.
Goyal L, DiToro D, Hollebecque A, Bridgewater JA, Shimura M, Kano A, Okamura S, Silhavy JL, Wacheck V, Halim A, Meric-Bernstam F. Goyal L, et al. Among authors: okamura s. Ann Oncol. 2024 Dec 11:S0923-7534(24)04976-7. doi: 10.1016/j.annonc.2024.11.017. Online ahead of print. Ann Oncol. 2024. PMID: 39672383 Free article.
Phase II trial evaluating the long-term efficacy and peripheral sensory neuropathy of capecitabine plus oxaliplatin (XELOX) as adjuvant therapy in Japanese patients with operated stage III colon cancer.
Hata T, Uemura M, Danno K, Yoshioka S, Matsuda C, Kagawa Y, Shingai T, Suzuki Y, Tei M, Tanida T, Komori T, Okamura S, Ota H, Takemoto H, Ogino T, Miyoshi N, Yamamoto H, Murata K, Doki Y, Eguchi H. Hata T, et al. Among authors: okamura s. Sci Rep. 2024 Nov 2;14(1):26434. doi: 10.1038/s41598-024-73222-0. Sci Rep. 2024. PMID: 39488510 Free PMC article. Clinical Trial.
Development of a novel treatment based on PKMYT1 inhibition for cisplatin-resistant bladder cancer with miR-424-5p-dependent cyclin E1 amplification.
Fukumoto W, Okamura S, Tamai M, Arima J, Kawahara I, Fukuda I, Mitsuke A, Sakaguchi T, Sugita S, Matsushita R, Tatarano S, Yamada Y, Nakagawa M, Enokida H, Yoshino H. Fukumoto W, et al. Among authors: okamura s. BMC Cancer. 2024 Oct 29;24(1):1333. doi: 10.1186/s12885-024-13109-5. BMC Cancer. 2024. PMID: 39472827 Free PMC article.
888 results